NPS Pharmaceuticals (NASDAQ:NPSP) has an orphan blockbuster on its hands. The company is giddy with excitement over the successful launch of its recently approved therapy. Priced at $295,000 per year, teduglutide, marketed in the US as Gattex and internationally as Revestive, raised a great deal of skepticism earlier this year. I'm going to take a closer look at the US launch of Gattex and show you why I believe NPS will pass $2 billion in annual teduglutide sales within the next five years.
The costs of short bowel syndrome
Short bowel syndrome is an extremely debilitating condition that prior to the launch of teduglutide was largely untreatable. The condition typically results from the surgical resection of the intestine...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|